Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs
暂无分享,去创建一个
K. Khunti | M. Jørgensen | K. Birkeland | A. Fu | N. Hammar | J. Bodegård | J. Wilding | M. Kosiborod | R. Holl | N. Arya | P. Fenici | M. Thuresson | M. Cavender | A. Norhammar | Nikita Arya
[1] 宏明 林,et al. DPP-4(dipeptidyl peptidase-4)阻害薬内服後に発症した水疱性類天疱瘡患者の臨床病型の検討 , 2018 .
[2] K. Mahaffey,et al. Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS‐R trials , 2017, Diabetes, obesity & metabolism.
[3] J. Eriksson,et al. Novel oral glucose‐lowering drugs are associated with lower risk of all‐cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes , 2017, Diabetes, obesity & metabolism.
[4] V. Andriukaitis. Directorate General of Health and Food Safety , 2017 .
[5] Petra Kaufmann,et al. Transforming Evidence Generation to Support Health and Health Care Decisions. , 2016, The New England journal of medicine.
[6] R. Califf,et al. Real-World Evidence - What Is It and What Can It Tell Us? , 2016, The New England journal of medicine.
[7] Darren K Mcguire,et al. Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus. , 2016, European heart journal.
[8] H. Bøtker,et al. Positive predictive value of cardiovascular diagnoses in the Danish National Patient Registry: a validation study , 2016, BMJ Open.
[9] D. Fitchett,et al. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. , 2016, Circulation.
[10] J. Eriksson,et al. Incidence, prevalence and mortality of type 2 diabetes requiring glucose-lowering treatment, and associated risks of cardiovascular complications: a nationwide study in Sweden, 2006–2013 , 2016, Diabetologia.
[11] J. McMurray,et al. SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms? , 2016, Diabetologia.
[12] S. Solomon,et al. Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting: Evidence From the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF). , 2016, Circulation.
[13] M. M. Rahman,et al. Worldwide trends in diabetes since 1980 : pooled analysis of 751 population-based measurement studies with over 4 . 4 million participants , 2016 .
[14] M. Fischereder,et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2016, The New England journal of medicine.
[15] T. Byers. Excess Mortality among Persons with Type 2 Diabetes. , 2016, The New England journal of medicine.
[16] B. Zinman,et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial , 2016, European heart journal.
[17] Lucía Cea Soriano,et al. Validity and completeness of colorectal cancer diagnoses in a primary care database in the United Kingdom† , 2015, Pharmacoepidemiology and drug safety.
[18] B. Zinman,et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.
[19] S. Nygård,et al. [Diagnostic accuracy for heart failure – data from the Akershus Cardiac Examination 2 Study]. , 2015, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.
[20] Deepak L. Bhatt,et al. Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and Death: Outcomes at 4 Years From the Reduction of Atherothrombosis for Continued Health (REACH) Registry , 2015, Circulation.
[21] J. Roy,et al. Use of demographic and pharmacy data to identify patients included within both the Clinical Practice Research Datalink (CPRD) and The Health Improvement Network (THIN) , 2015, Pharmacoepidemiology and drug safety.
[22] M. Pencina,et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. , 2015, The New England journal of medicine.
[23] Daniel F. Freitag,et al. Association of Cardiometabolic Multimorbidity With Mortality. , 2015, JAMA.
[24] K. Bhaskaran,et al. Data Resource Profile: Clinical Practice Research Datalink (CPRD) , 2015, International journal of epidemiology.
[25] Z. Vassilev,et al. Diabetes, cardiovascular morbidity, and risk of age-related macular degeneration in a primary care population. , 2015, Investigative ophthalmology & visual science.
[26] L. Håheim,et al. Agreement between referral information and discharge diagnoses according to Norwegian elective treatment guidelines – a cross-sectional study , 2014, BMC Health Services Research.
[27] A. Bate,et al. Incidence Rates and Trends of Hip/Femur Fractures in Five European Countries: Comparison Using E-Healthcare Records Databases , 2014, Calcified Tissue International.
[28] S. Johansson,et al. Use of proton pump inhibitors and the risk of coronary events in new users of low-dose acetylsalicylic acid in UK primary care , 2013, Thrombosis and Haemostasis.
[29] Deepak L. Bhatt,et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. , 2013, The New England journal of medicine.
[30] Update of mortality attributable to diabetes for the IDF Diabetes Atlas: estimates for the year 2011. , 2013, Diabetes research and clinical practice.
[31] J. Stevens,et al. The Atherosclerosis Risk in Communities Study , 2013 .
[32] T. V. van Staa,et al. Recent advances in the utility and use of the General Practice Research Database as an example of a UK Primary Care Data resource , 2012, Therapeutic advances in drug safety.
[33] M. Hernán,et al. Beyond the intention-to-treat in comparative effectiveness research , 2012, Clinical trials.
[34] S. Johansson,et al. Hospitalised ischaemic cerebrovascular accident and risk factors in a primary care database , 2011, Pharmacoepidemiology and drug safety.
[35] A. Bourke,et al. Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates. , 2011, Informatics in primary care.
[36] J. Ludvigsson,et al. External review and validation of the Swedish national inpatient register , 2011, BMC public health.
[37] Wolfgang Viechtbauer,et al. Conducting Meta-Analyses in R with the metafor Package , 2010 .
[38] J. Danesh,et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. , 2010, Lancet.
[39] The Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies , 2010, The Lancet.
[40] Ana Ruigómez,et al. Validation of ischemic cerebrovascular diagnoses in the health improvement network (THIN) , 2010, Pharmacoepidemiology and drug safety.
[41] J. Coresh,et al. The Association of Hemoglobin A1c With Incident Heart Failure Among People Without Diabetes: The Atherosclerosis Risk in Communities Study , 2010, Diabetes.
[42] M. Wallander,et al. Study of a cohort of patients newly diagnosed with depression in general practice: prevalence, incidence, comorbidity, and treatment patterns. , 2010, Primary care companion to the Journal of clinical psychiatry.
[43] M. Wallander,et al. Prevalence, incidence, morbidity and treatment patterns in a cohort of patients diagnosed with anxiety in UK primary care. , 2010, Family practice.
[44] Elizabeth A Stuart,et al. Matching methods for causal inference: A review and a look forward. , 2010, Statistical science : a review journal of the Institute of Mathematical Statistics.
[45] L. Smeeth,et al. Validation and validity of diagnoses in the General Practice Research Database: a systematic review , 2010, British journal of clinical pharmacology.
[46] T. Matsuyama. [GLP-1 (glucagon-like peptide 1)]. , 2005, Nihon rinsho. Japanese journal of clinical medicine.
[47] M. Wallander,et al. Acid-suppressive Drugs and Community-acquired Pneumonia , 2009, Epidemiology.
[48] James M. Robins,et al. Observational Studies Analyzed Like Randomized Experiments: An Application to Postmenopausal Hormone Therapy and Coronary Heart Disease , 2008, Epidemiology.
[49] L. Køber,et al. Accuracy of a heart failure diagnosis in administrative registers , 2008, European journal of heart failure.
[50] David M. Adamson,et al. HealtH ReseaRcH Data foR tHe Real WoRlD: tHe MaRketscan ® Databases , 2008 .
[51] W. Bilker,et al. Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research , 2007, Pharmacoepidemiology and drug safety.
[52] Garnet L Anderson,et al. Statistical Issues Arising in the Women's Health Initiative , 2005, Biometrics.
[53] E. Ingelsson,et al. The validity of a diagnosis of heart failure in a hospital discharge register , 2005, European journal of heart failure.
[54] Peter C Austin,et al. Comparison of Coding of Heart Failure and Comorbidities in Administrative and Clinical Data for Use in Outcomes Research , 2005, Medical care.
[55] W. Hundley,et al. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. , 2004, Diabetes care.
[56] P D Cleary,et al. Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores. , 2001, Journal of clinical epidemiology.
[57] N. Laird,et al. Meta-analysis in clinical trials. , 1986, Controlled clinical trials.
[58] W. Kannel,et al. Role of diabetes in congestive heart failure: the Framingham study. , 1974, The American journal of cardiology.